人硫氧还蛋白真核载体的构建及表达

目的构建人硫氧还蛋白基因的重组真核表达载体。方法人硫氧还蛋白的cDNA克隆至pGEM-TEasy载体,经DNA测序证明后,将其克隆至真核表达载体pShttle构建重组pShttle-hTRX,pShttle-hTRX转染Hela细胞系进行瞬时表达,通过Westernblot、免疫组化、活性测定、酶切、PCR扩增等方法证实构建载体的正确性。结果构建携带人硫氧还蛋白基因的真核表达载体pShttle-hTRX,转染HeLa细胞后可检测到hTRX的转录和表达。结论正确构建了携带人硫氧还蛋白基因的真核表达载体,本结果可用于探讨硫氧还蛋白的生物学作用。     

HBx基因真核表达载体的构建及表达

目的 构建重组HBx蛋白的真核表达载体pIRES2-AcGFP-HBx.方法 设计合成HBx基因的特异性PCR引物.PCR扩增获得HBx基因序列;将HBx基因序列克隆人T载体(pGEM-T-HBx);再用限制性内切酶BglⅡ和EcoR Ⅰ双酶切下目的片段,将其亚克隆人真核表达载体pIRES2-AcGFP;双酶切(Bgl Ⅱ和EcoR Ⅰ)和序列测定鉴定重组子;脂质体包裹pIRES2-AcGFP-HBx转染入HepG2细胞,G418筛选得到稳定表达HBx的细胞克隆,Western blot检测HBx蛋白在转染细胞中的表达情况.结果 PCR扩增获得全长HBx基因序列;双酶切筛选得到阳性重组子,测序分析证实插入序列正确;转染plRES2-AcGFP-HBx的HepG2细胞,荧光显微镜可观察到GFP的表达,Western blot 证实表达HBx蛋白.结论 成功构建重组HBx基因真核表达载体,获得稳定表达HBx蛋白的HepG2细胞株,为深入研究HBx蛋白的生物学功能提供实验条件.     

人miR-205真核表达载体的构建及鉴定

目的构建真核表达载体pcDNA3.1(+)-miR-205,并使其在肾上腺皮质癌细胞SW-13中稳定表达。方法依据miRbase数据库中pre-miR-205序列设计引物,PCR扩增pre-miR-205基因并将其克隆至线性化的pcD-NA3.1(+)质粒中,获得重组表达载体pcDNA3.1(+)-miR-205,经双酶切及测序分析后,将其及对照空载体转染肾上腺皮质癌SW-13细胞,采用实时定量RCR法鉴定miR-205在SW-13细胞中表达。结果酶切和测序结果均证实pcDNA3.1(+)-205重组质粒构建成功,经实时定量RCR检测表明转染pcDNA3.1(+)-205的SW-13细胞中miR-205阳性高表达。结论真核表达载体pcDNA3.1(+)-205在SW-13中稳定转染,为进一步研究miR-205在肾上腺皮质癌细胞SW-13中的功能及基因调控机制奠定了实验基础。     

人白细胞介素10真核表达载体的构建及表达

目的 建立人白细胞介素10(hIL-10)真核表达系统并观察其在HeLa细胞中的表达。方法 用RT-PCR方法自活化的人外周血淋巴细胞扩增hIL-10 cDNA，将其克隆至pMDl8-T中，测序正确后，再定向插入真核表达载体pCIneo中，经脂质体介导转染HeLa细胞，检测其在细胞内外的表达和分泌。结果 RT-PCR扩增的hIL-10 cDNA序列与GenBank中hIL-10 cDNA序列一致；构建了真核重组表达载体pCIneo-hIL-10；转染HeLa细胞后可检测到hIL-10的转录和表达。结论 成功构建了hIL-10真核表达系统，为今后的临床研究及基因工程药物的生产奠定基础。     

人肥大细胞类糜蛋白酶分泌型真核表达载体的构建

目的构建人肥大细胞类糜蛋白酶（MC—Chy）分泌型真核表达载体。方法以MC-Chy基因的质粒pDEST17／CMA为模板,通过PCR扩增出融合有免疫球蛋白K链信号肽的人MC—Chy基因,定向克隆至真核表达载体pcDNA3．1,通过PCR、酶切和DNA测序鉴定。结果PCR扩增出免疫球蛋白K链融合人MC-Chy基因,DNA序列测定结果显示目的基因片段正确插入真核表达载体pcDNA3．1。结论成功构建了人MC-Chy分泌型真核表达载体,为下一步重组类糜蛋白酶的制备及其功能的深入研究奠定了基础。     

恶性疟原虫FCC1/HN株CTP基因真核表达载体的构建

目的构建恶性疟原虫CTP 基因的真核表达载体,以便进一步研究其功能. 方法根据Genbank 已发表恶性疟原虫CTP基因序列(序列号为X084041),自行设计并合成了一对引物,通过聚合酶链反应扩增出CTP基因,经HindⅢ和BamHⅠ消化后定向克隆入测序载体pUC19,构建重组质粒pUC19-CTP.经双酶切、PCR扩增和序列测定,证实插入片段与已知CTP编码序列完全相同.用HindⅢ和BamHⅠ消化pUC19-CTP,将双酶切下的CTP编码基因片段定向亚克隆入真核表达载体pcDNA3. 结果经双酶切和PCR扩增鉴定证实CTP基因正向插入真核表达载体pcDNA3中. 结论真核表达质粒pcDNA3-CTP构建成功.     

前列腺癌特异突变DNA聚合酶β真核表达载体构建及鉴定

目的 构建前列腺癌(PCa)特异突变DNA聚合酶β(polβ)真核表达载体.方法 提取有特异DNA polβ突变的PCa组织的总RNA,通用引物逆转录成cDNA;用设计带有接头的DNA polβ全基因引物,PCR扩增PCa组织中呈现的突变型DNA polβ全基因;构建T-A克隆并进行重组体的筛选鉴定;亚克隆入表达载体pcDNA3.1并进行重组体的筛选和鉴定.结果 PCa特异突变DNA polβ基因扩增选择出P4(MI-polβ)和P5(M2-polβ)两个标本,构建重组有特定突变位点的polβ目的 基因的pcDNA3.1真核表达载体,经PCR扩增获得2个阳性集落.结论 经鉴定成功构建2例PCa特异突变DNA polβ真核表达载体(pcDNA3.1-M1 and peDNA3.1-M2).     

人DC-SIGN真核表达载体的构建及在K-562细胞中的表达

目的构建含人DC-SIGN基因的真核表达载体,探讨DC-SIGN在K-562细胞中的表达,为研究丙型肝炎病毒(HCV)与DC-SIGN的相互作用奠定基础.方法分离人外周血单个核细胞,体外诱导分化为树突状细胞(DC);提取细胞总RNA并反转录为cDNA,设计上下游引物,利用PCR技术扩增DC-SIGN片段,连接入克隆载体pGEM-T easy;应用双酶切回收基因片段,定向克隆入真核表达载体pCDNA3.1;通过脂质体介导的基因转染技术将pCDNA3.1-DC-SIGN和空载体转入K-562细胞,应用G-418筛选稳定表达DC-SIGN的K-562细胞,以DC-SIGN单抗通过免疫荧光法检测K-562细胞的表达产物.结果 PBMC体外成功刺激分化为DC,含DC-SIGN基因的克隆载体pGEM-DC-SIGN经酶切、PCR及测序鉴定分析正确,pCDNA3.1-DC-SIGN经酶切、PCR鉴定分析正确,DC-SIGN可在K-562细胞表面稳定表达.结论 DC-SIGN可在K-562细胞中大量表达,为进一步研究DC-SIGN在HCV感染中的作用奠定了基础.     

增强型绿色荧光蛋白真核表达载体的构建和表达

目的　构建增强型绿色荧光蛋白(Enhanced green fluorescent protein, EGFP)编码基因的真核表达载体 pcDNA3.1(+) GFP,并观察其在Hep 2细胞中的表达情况。　方法　据已知的EGFP基因序列,设计合成 1 对引物,并引入Hind Ⅲ和EcoR Ⅴ酶切位点。应用PCR技术,从含有 EGFP的 pAdTrack CMV中扩增 EGFP编码基因。通过 TA连接将其克隆入pGEM T easy载体,经PCR及限制性内切酶鉴定后,插入真核表达质粒pcDNA3.1(+)中,转化Esche richia coli DH5α感受态细胞,于Amp+ LB平板上筛选阳性克隆。重组子经 Hind Ⅲ和EcoRⅤ双酶切、PCR鉴定,将该载体转染人喉癌细胞 Hep 2 后 48 h观察 EGFP表达情况。　结果　成功构建了含 EGFP 编码基因的真核表达载体pcDNA3.1(+) GFP,并成功转染Hep 2细胞,在倒置荧光显微镜下呈现绿色光。　结论　获得可产生绿色荧光的 EG FP,能方便地用作报告基因和筛选标记。     

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues

This study investigated the feasibility of using immunohistochemistry (IHC) instead of PCR to detect BRAF V600E mutant protein in papillary thyroid carcinoma (PTC), and to determine the value of using preoperative BRAF V600E mutant protein by IHC to assist in the diagnosis of thyroid nodule patients with Hashimoto''s thyroiditis (HT).The expression of BRAFV600E mutant protein was measured in 23 cases of HT+PTC, 31 cases of PTC, and 28 cases of HT by IHC, followed by PCR in the same samples for validation. SPSS 19.0 software was used for statistical analysis.The sensitivity and specificity of IHC to detect BRAF V600E mutation were 100% and 42.86%, respectively. In addition, the mutation rate of BRAF V600E protein in the HT+PTC group (34.78%, 8/23) was lower than that in the PTC group (80.65%, 25/31).The application of IHC to detect BRAF V600E mutant protein has good sensitivity but not specificity to diagnose PTC. IHC can be used as a preliminary screening method to detect BRAF V600E mutation. The strongly positive (+++) staining of IHC potently indicated BRAF V600E gene mutation. For suspicious thyroid nodules combined with HT, the detection of BRAF V600E mutant protein with IHC alone is not of great significance for differentiating benign and malignant nodules.     

登革病毒prM基因真核表达载体的构建及在白纹伊蚊细胞C6/36中的表达

目的　构建登革病毒prM基因重组表达质粒并在白纹伊蚊细胞C6 / 36中表达。方法　将prM基因亚克隆入真核表达载体 pEGFP -N3,转化大肠杆菌JM 10 9,筛选阳性克隆进行PCR及酶切鉴定 ,将获得的重组质粒以脂质体法转化白纹伊蚊C6 / 36细胞并使其表达 ,利用RT -PCR法检测目的基因的转录 ,Western -blot检测融合蛋白的表达。结果　成功构建了 pEGFP -prM重组质粒 ,RT -PCR证明 prM基因在蚊细胞内的转录 ,Western -blot检测到 prM -GFP融合蛋白的表达。结论　成功构建登革了病毒 prM基因重组表达质粒并在白纹伊蚊细胞C6 / 36中表达 ,为进一步研究细胞内免疫的分子机制及构建转基因蚊虫奠定了基础     

BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series

Purpose

To describe the clinical, radiographic and surgical outcomes in a cohort of patients with BRAF V600E mutant papillary craniopharyngiomas.

Methods

A retrospective review was performed to identify all patients with a histological diagnosis of CP operated upon at a single institution between 2005 and 2017. All cases with adequate material were sequenced to confirm the presence of BRAF V600E mutation.

Results

Sixteen patients were included in the present study. Approach was endoscopic endonasal (EEA) in 14 and transcranial (TCA) in 2. All patients were adult with an average age of 50 years (24–88). Radiographic review demonstrated that the majority (93.7%) were suprasellar and twelve (75%) had third ventricular involvement. No tumor showed evidence of calcifications and 68.7% were mixed solid-cystic. All patients had some evidence of hypopituitarism and 62.5% had hypothalamic disturbances. GTR was achieved in 11/14 (78.6%) EEA and 0/2 (0%) TCA (p?<?0.05). The mean length of stay was 17.5 days in the TCA group and 7.6 days in the EEA group (p?<?0.05). There were no CSF leaks. Post-operatively, eleven (68.7%) developed new DI or new hypopituitarism. Nine increased their BMI with a mean increase of 12.3%, whereas six patients lost weight with a mean decrease of 5.3%.

Conclusions

BRAF V600E mutant papillary tumors represent a clearly distinct clinical-pathological entity of craniopharyngiomas. These are generally non-calcified suprasellar tumors that occur in adults. These distinct characteristics may someday lead to upfront chemotherapy. When surgery is necessary, EEA may be preferred over TCA.

     

人CCR7基因真核表达载体构建及表达

目的构建人CCR7基因真核表达质粒,使其在真核细胞中稳定表达,为其临床应用奠定基础。方法以RT—PCR法从临床肺腺癌标本中扩增出CCR7编码区序列,定向克隆至载体pEGFP—N1中构建质粒pEGFP—CCR7,采用脂质体介导的基因转染技术将重组质粒DNA导人肺腺癌A549细胞中,加入G418对细胞进行筛选获得稳定表达CCR7的细胞,并用流式细胞仪对重组质粒的表达进行鉴定。结果PCR、酶切及测序结果证明重组质粒pEGFP—CCR7构建正确,荧光显微镜及流式细胞术在稳定转染A549细胞中检测到人CCR7的表达。结论人CCR7基因真核表达质粒已成功构建并稳定转染肺癌A549细胞株;本研究为临床应用提供了实验依据。     

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer

Amelanotic melanoma is a rare type of melanoma that shows little or no melanin pigmentation. When tumor lesions are not detected in cutaneous sites, the presence of melanin is the hallmark sign of malignant melanoma. We herein report a case of amelanotic melanoma with a BRAF V600E mutation mimicking primary lung cancer that was finally diagnosed on an autopsy. The current case suggests important caveats for the differential diagnosis of patients with BRAF V600E mutation-positive poorly differentiated lung tumors. In terms of the pathological diagnosis, routine immunohistochemical staining may be useful, especially in patients with a poorly differentiated lung tumor without TTF-1 expression.     

TRAIL真核表达质粒的构建及其在膀胱癌细胞中的表达

目的 构建TRAIL真核表达质粒并初步研究其在膀胱癌细胞中的表达.方法 提取Jurkat淋巴瘤细胞总RNA,进行RT-PCR反应,产物测序证实后插入经同样酶切的质粒PcDNA3.1中,构建成真核表达质粒PcD-NA3.1-TRAIL.Western blot法鉴定其能否在膀胱癌细胞中表达.结果 Jurkat淋巴瘤细胞的RT-PCR产物经测序证实为TRAIL基因的全长序列;经酶切、测序证实成功构建PcDNA3.1-TRIAL质粒;Western blot结果显示,转染上述质粒的膀胱癌细胞中有TRAIL的表达.结论 成功构建了表达全长TRAIL的真核表达载体,并通过Westernblot验证其可在膀胱癌细胞中表达.